Clinical features of depressed patients who do and do not improve with placebo

The substantial placebo response in depression confounds treatment decisions and the assessment of new therapies. Improvement with placebo occurs infrequently in patients with chronic depression and in those with pituitary-adrenocortical hyperfunction, but other consistent predictors of placebo response have not been detected. We divided 241 moderately to severely depressed patients who had received placebo on a double-blind basis for 3 to 6 weeks into responders (greater than or equal to 50% improvement in Hamilton depression score, final Hamilton depression score less than or equal to 10), extreme nonresponders (less than 25% improvement), and partial responders (all others). Improvement with placebo was associated with a relatively short illness, a precipitating event, depression of only moderate global severity, and a good response to previous antidepressant treatment. These observations suggest that depressed patients who do and do not recover with placebo have different conditions that have not yet been fully characterized.

[1]  S. C. Rogers,et al.  A Statistical Review of Controlled Trials of Imipramine and Placebo in the Treatment of Depressive Illnesses , 1975, British Journal of Psychiatry.

[2]  F. Quitkin,et al.  Baseline characteristics of 10-day placebo washout responders in antidepressant trials , 1987, Psychiatry Research.

[3]  W. Brown,et al.  Placedo response in depression: A search for predictors , 1988, Psychiatry Research.

[4]  C. Mazure,et al.  Does melancholia predict response in major depression? , 1990, Journal of affective disorders.

[5]  D. Klein,et al.  Efficacy of desipramine in depressed outpatients. Response according to research diagnosis criteria diagnoses and severity of illness. , 1983, Archives of general psychiatry.

[6]  A. Binitie.  A Factor-Analytical Study of Depression Across Cultures (African and European) , 1975, British Journal of Psychiatry.

[7]  H. Beecher,et al.  The powerful placebo. , 1955, Journal of the American Medical Association.

[8]  K. Rickels,et al.  PREDICTORS OF RESPONSE TO AMITRIPTYLINE AND PLACEBO IN THREE OUTPATIENT TREATMENT SETTINGS , 1973, The Journal of nervous and mental disease.

[9]  M. Åsberg,et al.  A New Depression Scale Designed to be Sensitive to Change , 1979, British Journal of Psychiatry.

[10]  N. Voudouris,et al.  Conditioned placebo responses. , 1985, Journal of personality and social psychology.

[11]  T. Crook,et al.  The endogenous—neurotic distinction as a predictor of response to antidepressant drugs , 1976, Psychological Medicine.

[12]  R. O. Friedel,et al.  Prediction of tricyclic antidepressant response: a critical review. , 1976, Archives of general psychiatry.

[13]  R. Shrivastava,et al.  Pre-treatment pituitary-adrenocortical status and placebo response in depression. , 1987, Psychopharmacology bulletin.

[14]  P. Joyce,et al.  Predictors of drug response in depression. , 1989, Archives of general psychiatry.

[15]  S. Dager,et al.  Chronicity of depressive episode in relation to antidepressant-placebo response. , 1991, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.

[16]  S. Olson,et al.  Absence of Placebo Response in Obsessive-Compulsive Disorder , 1990, The Journal of nervous and mental disease.

[17]  A. Rush,et al.  Which depressions respond to placebo? , 1986, Psychiatry Research.

[18]  L. Kiloh,et al.  Prognostic Factors in Treatment of Depressive States with Imipramine , 1962, British medical journal.

[19]  D. Klein.  Endogenomorphic depression. A conceptual and terminological revision. , 1974, Archives of general psychiatry.

[20]  L. Covi,et al.  The Hopkins Symptom Checklist (HSCL): a self-report symptom inventory. , 1974, Behavioral science.